RJA
FOLD

Raymond James & Associates’s Amicus Therapeutics FOLD Stock Holding History

Raymond James & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,735
Closed -$131K – 3866
2023
Q3 		$131K Sell
10,735
-13,345
-55% -$172K ﹤0.01% 3551
2023
Q2 		$302K Buy
+24,080
New +$286K ﹤0.01% 3253
2023
Q1 		– Sell
-10,273
Closed -$125K – 3943
2022
Q4 		$125K Buy
+10,273
New +$116K ﹤0.01% 3592
2022
Q1 		– Sell
-27,687
Closed -$320K – 4168
2021
Q4 		$320K Buy
27,687
+1,459
+6% +$16.3K ﹤0.01% 3397
2021
Q3 		$250K Sell
26,228
-8,389
-24% -$85.8K ﹤0.01% 3543
2021
Q2 		$334K Sell
34,617
-76,229
-69% -$744K ﹤0.01% 3360
2021
Q1 		$1.09M Buy
110,846
+33,199
+43% +$514K ﹤0.01% 2445
2020
Q4 		$1.79M Sell
77,647
-3,982
-5% -$81.4K ﹤0.01% 1952
2020
Q3 		$1.15M Sell
81,629
-15,670
-16% -$228K ﹤0.01% 2097
2020
Q2 		$1.47M Buy
97,299
+7,130
+8% +$86.9K ﹤0.01% 1914
2020
Q1 		$833K Buy
90,169
+6,700
+8% +$63.7K ﹤0.01% 2104
2019
Q4 		$813K Buy
83,469
+10,522
+14% +$96.3K ﹤0.01% 2406
2019
Q3 		$585K Buy
72,947
+17,020
+30% +$185K ﹤0.01% 2543
2019
Q2 		$698K Buy
55,927
+5,747
+11% +$72.9K ﹤0.01% 2437
2019
Q1 		$682K Buy
50,180
+12,134
+32% +$148K ﹤0.01% 2451
2018
Q4 		$364K Sell
38,046
-14,666
-28% -$161K ﹤0.01% 2751
2018
Q3 		$637K Sell
52,712
-2,449
-4% -$34.2K ﹤0.01% 2539
2018
Q2 		$862K Sell
55,161
-964
-2% -$14.6K ﹤0.01% 2318
2018
Q1 		$844K Sell
56,125
-136,853
-71% -$2.08M ﹤0.01% 2255
2017
Q4 		$2.78M Buy
192,978
+2,414
+1% +$33.2K 0.01% 1474
2017
Q3 		$2.87M Buy
+190,564
New +$2.52M 0.01% 1392
2016
Q2 		– Sell
-21,324
Closed -$180K – 3048
2016
Q1 		$180K Sell
21,324
-3,676
-15% -$26K ﹤0.01% 2602
2015
Q4 		$243K Buy
+25,000
New +$225K ﹤0.01% 2274

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Raymond James & Associates's FOLD Position: Q4 2023 in Review

Raymond James & Associates sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 10,735 shares — an estimated $131K sold.

Raymond James & Associates first reported a position in FOLD in Q4 2015 and held it in 23 quarters. The position peaked at $2.87M in Q3 2017. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

  • Raymond James & Associates reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,735 Amicus Therapeutics shares in Q4 2023, an estimated $131K.
  • Raymond James & Associates first reported a position in Amicus Therapeutics in Q4 2015 and held it in 23 quarters.
  • Raymond James & Associates's Amicus Therapeutics position peaked at $2.87M in Q3 2017.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.